$XNCR
Xencor Inc Stock $xncr

$xncr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000132673224000006 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$12.80M	$44.69M	$168.3M
YoY Change	-32.63%	106.8%	2.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.79M	$15.27M	$53.38M
YoY Change	-1.15%	19.77%	12.4%
% of Gross Profit
Research & Development	$56.87M	$63.05M	$253.6M
YoY Change	-11.66%	22.53%	27.08%
% of Gross Profit
Depreciation & Amortization	$3.035M	$3.228M	$11.50M
YoY Change	35.19%	49.51%	30.67%
% of Gross Profit
Operating Expenses	$70.66M	$78.32M	$307.0M
YoY Change	-9.79%	21.98%	24.26%
Operating Profit	-$57.86M		-$138.6M
YoY Change	-2.54%		68.1%
Interest Expense	$5.296M	$20.19M	$22.53M
YoY Change	-88366.67%	-33.09%	-20.25%
% of Operating Profit
Other Income/Expense, Net	-$10.85M	$20.18M	$18.20M
YoY Change	676.39%	34687.93%	-34.92%
Pretax Income	-$68.71M	-$13.45M	-$120.4M
YoY Change	13.08%	7.99%	120.96%
Income Tax	$0.00	$5.811M	$5.811M
% Of Pretax Income
Net Earnings	-$68.03M	-$19.10M	-$126.1M
YoY Change	11.96%	58.61%	128.5%
Net Earnings / Revenue	-531.51%	-42.74%	-74.92%
Basic Earnings Per Share	-$1.11		-$2.08
Diluted Earnings Per Share	-$1.11	-$0.31	-$2.08
COMMON SHARES
Basic Shares Outstanding	61.12M shares	60.88M shares	60.50M shares
Diluted Shares Outstanding	61.21M shares		60.50M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$535.9M	$593.7M	$593.7M
YoY Change	-8.86%	-4.71%	-4.71%
Cash & Equivalents	$31.03M	$53.79M	$53.79M
Short-Term Investments	$504.9M	$539.9M	$539.9M
Other Short-Term Assets	$16.74M	$18.15M	$18.15M
YoY Change	-24.25%	-22.07%	-22.07%
Inventory
Prepaid Expenses
Receivables	$9.580M	$11.29M	$11.29M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$562.3M	$623.2M	$623.2M
YoY Change	-10.75%	-7.73%	-7.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$63.54M	$66.12M	$100.1M
YoY Change	-4.72%	11.73%	6.96%
Goodwill
YoY Change
Intangibles	$18.85M	$18.66M
YoY Change	3.33%	0.88%
Long-Term Investments	$198.5M	$209.7M	$209.7M
YoY Change	266.21%	260.29%	260.29%
Other Assets	$498.0K	$648.0K	$1.028M
YoY Change	-16.86%	5.71%	67.7%
Total Long-Term Assets	$322.0M	$329.5M	$329.5M
YoY Change	85.66%	92.79%	92.79%
TOTAL ASSETS
Total Short-Term Assets	$562.3M	$623.2M	$623.2M
Total Long-Term Assets	$322.0M	$329.5M	$329.5M
Total Assets	$884.3M	$952.7M	$952.7M
YoY Change	10.06%	12.58%	12.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.01M	$13.91M	$13.91M
YoY Change	4.37%	37.93%	37.93%
Accrued Expenses	$13.49M	$23.56M	$27.00M
YoY Change	-10.89%	25.82%	15.2%
Deferred Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.951M	$6.332M	$6.332M
YoY Change
Total Short-Term Liabilities	$79.40M	$84.71M	$84.71M
YoY Change	22.05%	32.68%	32.68%
LONG-TERM LIABILITIES
Long-Term Debt	$12.49M	$14.64M	$14.64M
YoY Change
Other Long-Term Liabilities	$180.2M	$184.2M	$184.2M
YoY Change	228.96%	235.37%	235.37%
Total Long-Term Liabilities	$12.49M	$14.64M	$198.9M
YoY Change	-77.2%	-73.34%	262.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.40M	$84.71M	$84.71M
Total Long-Term Liabilities	$12.49M	$14.64M	$198.9M
Total Liabilities	$272.1M	$283.6M	$283.9M
YoY Change	127.05%	138.75%	139.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$532.4M	-$464.4M
YoY Change	33.42%	37.27%
Common Stock	$617.0K	$611.0K
YoY Change	1.98%	1.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$612.5M	$668.8M	$668.8M
YoY Change
Total Liabilities & Shareholders Equity	$884.3M	$952.7M	$952.7M
YoY Change	10.06%	12.58%	12.58%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$68.03M	-$19.10M	-$126.1M
YoY Change	11.96%	58.61%	128.5%
Depreciation, Depletion And Amortization	$3.035M	$3.228M	$11.50M
YoY Change	35.19%	49.51%	30.67%
Cash From Operating Activities	-$55.26M	$181.2M	$85.11M
YoY Change	80.5%	-841.71%	247.6%
INVESTING ACTIVITIES
Capital Expenditures	$132.0K	$1.706M	$18.45M
YoY Change	-98.78%	-84.35%	-52.08%
Acquisitions
YoY Change
Other Investing Activities	$33.38M	-$201.4M	-$89.81M
YoY Change	-43.74%	-668.24%	17.68%
Cash From Investing Activities	$32.32M	-$203.1M	-$111.1M
YoY Change	-32.87%	-927.48%	-7.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$186.0K	22.98M	$26.18M
YoY Change	-79.83%	1862.68%	359.17%
NET CHANGE
Cash From Operating Activities	-$55.26M	181.2M	$85.11M
Cash From Investing Activities	$32.32M	-203.1M	-$111.1M
Cash From Financing Activities	$186.0K	22.98M	$26.18M
Net Change In Cash	-$22.75M	1.059M	$228.0K
YoY Change	-223.31%	-17.78%	-100.25%
FREE CASH FLOW
Cash From Operating Activities	-$55.26M	$181.2M	$85.11M
Capital Expenditures	$132.0K	$1.706M	$18.45M
Free Cash Flow	-$55.39M	$179.5M	$66.66M
YoY Change	33.8%	-608.07%	-575.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	xncr	Equity Received In Connection With Sale Of Financial Assets EquityReceivedInConnectionWithSaleOfFinancialAssets	3300000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-395000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	23434000	usd
CY2023	xncr	Equity Securities Impairment EquitySecuritiesImpairment	0	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001326732
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	xncr	Defined Contribution Plan Annual Vesting Percentage Over Vesting Term DefinedContributionPlanAnnualVestingPercentageOverVestingTerm	0.33
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36182
CY2023	dei	Entity Registrant Name EntityRegistrantName	Xencor, Inc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-1622502
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	465 North Halstead Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Pasadena
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91107
CY2023	dei	City Area Code CityAreaCode	626
CY2023	dei	Local Phone Number LocalPhoneNumber	305-5900
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1502093347	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61120272	shares
CY2023	dei	Auditor Firm AuditorFirmId	49
CY2023	dei	Auditor Name AuditorName	RSM US LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53790000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53942000	usd
CY2023Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	497725000	usd
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	526689000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	42210000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	42431000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11290000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28997000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18145000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23283000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	623160000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	675342000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66124000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59183000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18663000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18500000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	380000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2023Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	145512000	usd
CY2022Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	3826000	usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	64210000	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	54383000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33995000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34419000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	648000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	613000	usd
CY2023Q4	us-gaap	Assets Assets	952692000	usd
CY2022Q4	us-gaap	Assets Assets	846266000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13914000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10088000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23564000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18728000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5782000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3435000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4708000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30320000	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	31682000	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0	usd
CY2023Q4	us-gaap	Debt Current DebtCurrent	6332000	usd
CY2022Q4	us-gaap	Debt Current DebtCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	84709000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	63844000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59025000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54926000	usd
CY2023Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	125183000	usd
CY2022Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14642000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	283559000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	118770000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60998191	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60998191	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59997713	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59997713	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	611000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	601000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1131266000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1072132000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1291000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6952000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-464372000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-338285000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	668796000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	727496000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	337000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	0	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	669133000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	727496000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	952692000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	846266000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	168338000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164579000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	275111000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	253598000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	199563000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	192507000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	53379000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47489000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38837000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	306977000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	247052000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	231344000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-138639000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-82473000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	43767000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18626000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4817000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	849000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-395000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	23434000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	39289000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18200000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27965000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38864000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120439000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54508000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	82631000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5811000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	673000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-126250000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-55181000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	82631000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-163000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-126087000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-55181000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	82631000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.37
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60503283	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59652461	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58379641	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60503283	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59652461	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60495455	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-126250000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-55181000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	82631000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8243000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5442000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1584000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-118007000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-60623000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	81047000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-163000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117844000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60623000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	81047000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	572444000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28920000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12281000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1837000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	81047000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36975000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	733504000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3610000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2092000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60623000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	48913000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	727496000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3412000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1977000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	500000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-118007000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	53755000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	669133000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-126250000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-55181000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	82631000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11498000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8799000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7491000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	13635000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-127000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3160000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	53755000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	48913000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36975000	usd
CY2023	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	1267000	usd
CY2022	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	1510000	usd
CY2021	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	934000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1379000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-145000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-462000	usd
CY2023	xncr	Noncash Consideration Received From Revenue Contracts NoncashConsiderationReceivedFromRevenueContracts	10000000	usd
CY2022	xncr	Noncash Consideration Received From Revenue Contracts NoncashConsiderationReceivedFromRevenueContracts	5397000	usd
CY2021	xncr	Noncash Consideration Received From Revenue Contracts NoncashConsiderationReceivedFromRevenueContracts	22379000	usd
CY2023	xncr	Equity Received In Connection With Sale Of Financial Assets EquityReceivedInConnectionWithSaleOfFinancialAssets	0	usd
CY2022	xncr	Equity Received In Connection With Sale Of Financial Assets EquityReceivedInConnectionWithSaleOfFinancialAssets	0	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	20988000	usd
CY2022	xncr	Equity Securities Impairment EquitySecuritiesImpairment	138000	usd
CY2021	xncr	Equity Securities Impairment EquitySecuritiesImpairment	762000	usd
CY2023	xncr	Noncash Interest Expense NoncashInterestExpense	681000	usd
CY2022	xncr	Noncash Interest Expense NoncashInterestExpense	0	usd
CY2021	xncr	Noncash Interest Expense NoncashInterestExpense	0	usd
CY2023	xncr	Increase Decrease In Accounts And Other Receivables And Contract With Customer Assets IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets	-17707000	usd
CY2022	xncr	Increase Decrease In Accounts And Other Receivables And Contract With Customer Assets IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets	-37387000	usd
CY2021	xncr	Increase Decrease In Accounts And Other Receivables And Contract With Customer Assets IncreaseDecreaseInAccountsAndOtherReceivablesAndContractWithCustomerAssets	42441000	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	1028000	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	530000	usd
CY2021	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-655000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5103000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-634000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13592000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-5782000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3826000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3913000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5047000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4836000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-715000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1840000	usd
CY2023	xncr	Increase Decrease In Lease Liabilities And Right Of Use Assets IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets	3250000	usd
CY2022	xncr	Increase Decrease In Lease Liabilities And Right Of Use Assets IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets	22976000	usd
CY2021	xncr	Increase Decrease In Lease Liabilities And Right Of Use Assets IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets	1211000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-30320000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6974000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-55321000	usd
CY2023	us-gaap	Increase Decrease In Loans Deferred Income IncreaseDecreaseInLoansDeferredIncome	-156865000	usd
CY2022	us-gaap	Increase Decrease In Loans Deferred Income IncreaseDecreaseInLoansDeferredIncome	0	usd
CY2021	us-gaap	Increase Decrease In Loans Deferred Income IncreaseDecreaseInLoansDeferredIncome	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	85111000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24485000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16853000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	693090000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	306607000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	485152000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	19000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	782905000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	387928000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	509597000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2803000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4910000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2682000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18448000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38494000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13299000	usd
CY2023	xncr	Payments Conversion Of Notes Receivable PaymentsConversionOfNotesReceivable	0	usd
CY2022	xncr	Payments Conversion Of Notes Receivable PaymentsConversionOfNotesReceivable	-5000000	usd
CY2021	xncr	Payments Conversion Of Notes Receivable PaymentsConversionOfNotesReceivable	5000000	usd
CY2023	xncr	Exercise Of Stock Options Investing Activity ExerciseOfStockOptionsInvestingActivity	0	usd
CY2022	xncr	Exercise Of Stock Options Investing Activity ExerciseOfStockOptionsInvestingActivity	0	usd
CY2021	xncr	Exercise Of Stock Options Investing Activity ExerciseOfStockOptionsInvestingActivity	842000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111065000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-119725000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46249000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3412000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3610000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12281000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1977000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2092000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28920000	usd
CY2023	xncr	Proceeds From Future Sale Of Royalties ProceedsFromFutureSaleOfRoyalties	20293000	usd
CY2022	xncr	Proceeds From Future Sale Of Royalties ProceedsFromFutureSaleOfRoyalties	0	usd
CY2021	xncr	Proceeds From Future Sale Of Royalties ProceedsFromFutureSaleOfRoyalties	0	usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	500000	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26182000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5702000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43038000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	228000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-89538000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20064000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53942000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143480000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163544000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54170000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53942000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143480000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	22000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	700000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	8243000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5442000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1584000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2462000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6155000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	24047000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive gain (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets.</span></div>
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30300000	usd
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	400000	usd
CY2022	xncr	Marketable Securities Impairment Losses And Recoveries MarketableSecuritiesImpairmentLossesAndRecoveries	0	usd
CY2023	xncr	Marketable Securities Impairment Losses And Recoveries MarketableSecuritiesImpairmentLossesAndRecoveries	0	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2300000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1300000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	8200000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-5400000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	100000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-400000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	23400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8540000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash, and marketable debt securities are financial instruments that potentially subject the Company to concentrations of risk. We invest our cash in corporate debt securities and U.S. sponsored agencies with strong credit ratings. We have established guidelines relative to diversification and maturities that are designed to help ensure safety and liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash are maintained at financial institutions, and at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. Amounts on deposit in excess of federally insured limits at December 31, 2023 and 2022 approximated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$53.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $53.6 million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have payables with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service providers that represent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our total payables and with two service providers that represented 45% of our total payables at December 31, 2023 and 2022, respectively. We rely on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> critical suppliers for the manufacture of our drug product for use in our clinical trials. While we believe that there are alternative vendors available, a change in manufacturing vendors could cause a delay in the availability of drug product and result in a delay of conducting and completing our clinical trials. No other vendor accounted for more than 10% of total payables at December 31, 2023 or 2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have receivables with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> customers and service providers that represent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our total receivables and with four customers and service providers that represent 91% of our total receivables at December 31, 2023 and 2022, </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. The receivables are related to cost share reimbursement and royalty revenues from our licensing and collaboration agreements. No other customer accounted for more than 10% of total receivables at December 31, 2023 or 2022.</span></div>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	53800000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	53600000	usd
CY2023	xncr	Number Of Primary Criteria To Determine Capitalization Of Patent NumberOfPrimaryCriteriaToDetermineCapitalizationOfPatent	3	criteria
CY2023	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	1300000	usd
CY2022	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	1500000	usd
CY2021	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	900000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	29469000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	28170000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18663000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18500000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1076000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1059000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	961000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	908000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	776000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3760000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5800000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53800000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48900000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37000000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-126087000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55181000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	82631000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60503283	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59652461	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58379641	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.42
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-126087000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55181000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	82631000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60503283	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59652461	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58379641	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2115814	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60503283	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59652461	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60495455	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.37
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1196268	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	xncr	Cash And Cash Equivalents And Marketable Securities Amortized Cost CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost	667455000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1379000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	77000	usd
CY2023Q4	us-gaap	Investments Investments	668757000	usd
CY2023Q4	us-gaap	Investments Investments	668757000	usd
CY2022Q4	xncr	Cash And Cash Equivalents And Marketable Securities Amortized Cost CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost	578424000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6945000	usd
CY2022Q4	us-gaap	Investments Investments	571482000	usd
CY2022Q4	us-gaap	Investments Investments	571482000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	497326000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	497725000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	144609000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	145511000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	641935000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	643236000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	417000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-74000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	95000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	74619000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	78000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	457591000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6940000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	3826000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-395000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	23434000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	39289000	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	18301000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-395000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	23434000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	20988000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	102350000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87472000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36226000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28289000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66124000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59183000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10100000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7400000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6300000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5800000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25258000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11447000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	17352000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-569000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-615000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	783000	usd
CY2023	xncr	Income Tax Reconciliation Research And Development Credit IncomeTaxReconciliationResearchAndDevelopmentCredit	-15821000	usd
CY2022	xncr	Income Tax Reconciliation Research And Development Credit IncomeTaxReconciliationResearchAndDevelopmentCredit	-9366000	usd
CY2021	xncr	Income Tax Reconciliation Research And Development Credit IncomeTaxReconciliationResearchAndDevelopmentCredit	-10492000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3131000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3384000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2424000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	1188000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	1449000	usd
CY2023	xncr	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	234000	usd
CY2022	xncr	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	44000	usd
CY2021	xncr	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	2599000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	44865000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20196000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-12761000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5811000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	673000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22466000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32898000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	53198000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	54825000	usd
CY2023Q4	xncr	Deferred Tax Asset Debt Securities Available For Sale Unrealized Gain Loss DeferredTaxAssetDebtSecuritiesAvailableForSaleUnrealizedGainLoss	-278000	usd
CY2022Q4	xncr	Deferred Tax Asset Debt Securities Available For Sale Unrealized Gain Loss DeferredTaxAssetDebtSecuritiesAvailableForSaleUnrealizedGainLoss	1573000	usd
CY2023Q4	xncr	Deferred Tax Assets Capitalized Lease Assets DeferredTaxAssetsCapitalizedLeaseAssets	6161000	usd
CY2022Q4	xncr	Deferred Tax Assets Capitalized Lease Assets DeferredTaxAssetsCapitalizedLeaseAssets	5564000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	18172000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	14484000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	34405000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3225000	usd
CY2023Q4	xncr	Deferred Tax Assets Tax Deferred Expense Capitalized Research And Experimental Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndExperimentalExpenditures	45783000	usd
CY2022Q4	xncr	Deferred Tax Assets Tax Deferred Expense Capitalized Research And Experimental Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndExperimentalExpenditures	21338000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	179907000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	133907000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	158099000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115010000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21808000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18897000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	2218000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	2885000	usd
CY2023Q4	xncr	Deferred Tax Liabilities License Costs DeferredTaxLiabilitiesLicenseCosts	136000	usd
CY2022Q4	xncr	Deferred Tax Liabilities License Costs DeferredTaxLiabilitiesLicenseCosts	124000	usd
CY2023Q4	xncr	Deferred Tax Liabilities Capitalized Legal Costs DeferredTaxLiabilitiesCapitalizedLegalCosts	6000	usd
CY2022Q4	xncr	Deferred Tax Liabilities Capitalized Legal Costs DeferredTaxLiabilitiesCapitalizedLegalCosts	9000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	10664000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6532000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	8784000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	9347000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21808000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	18897000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	43100000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	53755000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	48913000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36975000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	53755000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	48913000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36975000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	400000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6128000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8022000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9238000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9560000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9076000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	66435000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	108459000	usd
CY2023Q4	xncr	Lessee Operating Lease Liability Tenant Allowance LesseeOperatingLeaseLiabilityTenantAllowance	3252000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42747000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62460000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3435000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59025000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62460000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	8459000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6588000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4342000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	906000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	506000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	58000	usd
CY2023	us-gaap	Lease Cost LeaseCost	9365000	usd
CY2022	us-gaap	Lease Cost LeaseCost	7094000	usd
CY2021	us-gaap	Lease Cost LeaseCost	4400000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3253000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2869000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2773000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	168300000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164600000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	275100000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	168300000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164600000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	275100000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	168300000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164600000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	275100000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30300000	usd
CY2022Q4	xncr	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	0	usd
CY2023	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	20293000	usd
CY2023	xncr	Royalty Liability Payments RoyaltyLiabilityPayments	0	usd
CY2023	xncr	Royalty Liability Interest Expense Including Amortization Of Closing Costs RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts	681000	usd
CY2023Q4	xncr	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	20974000	usd
CY2023Q4	xncr	Royalty Liabilities Short Term Debt RoyaltyLiabilitiesShortTermDebt	6332000	usd
CY2023Q4	xncr	Royalty Liabilities Long Term Debt RoyaltyLiabilitiesLongTermDebt	14642000	usd
CY2023Q4	xncr	Royalty Liability Debt Long Term And Short Term Combined Amount RoyaltyLiabilityDebtLongTermAndShortTermCombinedAmount	20974000	usd
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.040
CY2023	xncr	Defined Contribution Plan Vesting Period DefinedContributionPlanVestingPeriod	P3Y
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1700000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1400000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001326732-24-000006-index-headers.html	Edgar Link	pending
0001326732-24-000006-index.html	Edgar Link	pending
0001326732-24-000006.txt	Edgar Link	pending
0001326732-24-000006-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xncr-20231231.htm	Edgar Link	pending
xncr-20231231.xsd	Edgar Link	pending
xncr-20231231xexx1047.htm	Edgar Link	pending
xncr-20231231xexx231.htm	Edgar Link	pending
xncr-20231231xexx311.htm	Edgar Link	pending
xncr-20231231xexx312.htm	Edgar Link	pending
xncr-20231231xexx321.htm	Edgar Link	pending
xncr-20231231xexx322.htm	Edgar Link	pending
xncr-20231231xexx97.htm	Edgar Link	pending
xncr-20231231_g1.jpg	Edgar Link	pending
xncr-20231231_cal.xml	Edgar Link	unprocessable
xncr-20231231_def.xml	Edgar Link	unprocessable
xncr-20231231_lab.xml	Edgar Link	unprocessable
xncr-20231231_pre.xml	Edgar Link	unprocessable
xncr-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XNCR
Xencor Inc Stock $xncr

2024 Q1 Form 10-K Financial Statement

#000132673224000006 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XNCR Xencor Inc Stock $xncr

2024 Q1 Form 10-K Financial Statement

#000132673224000006 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XNCR
Xencor Inc Stock $xncr